Advertisement

Topics

Latest "eRace Cancer" News Stories

17:14 EDT 16th July 2019 | BioPortfolio

Here are the most relevant search results for "eRace Cancer" found in our extensive news archives from over 250 global news sources.

More Information about eRace Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about eRace Cancer for you to read. Along with our medical data and news we also list eRace Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of eRace Cancer Companies for you to search.

Showing "eRace Cancer" News Articles 1–25 of 17,000+

Tuesday 16th July 2019

Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer

Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved Health Canada indication resulted in a 51% reduction in the risk of invasive disease recurrence or death at 2 years versus placebo after p...


Seattle Genetics Reports Second Quarter 2019 Financial Results

-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on Results from the EV-201 Pivotal Trial- -Topline Results from Tucatinib HER2CLIMB Pivotal Trial ...

As the 2020 campaign heats up, the Biden Cancer Initiative announced it's halting its operations. https://buff.ly/2kg2ePT 

As the 2020 campaign heats up, the Biden Cancer Initiative announced it's halting its operations. https://buff.ly/2kg2ePT 


Neutron Therapeutics to Install Its BNCT Cancer Therapy System into Japan’s Largest Private Hospital Chain

Neutron Therapeutics, Inc (NTI) has agreed with Tokushukai Medical Group (TMG) to install a nuBeam system for Boron-Neutron Capture Therapy (BNCT) at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan. Developed by NTI and having roots in technology originating at MIT, nuBeam is the world’s most powerful accelerator-based neutron source designed specifically to deliver this cu...

Israeli cancer treatment co P-Cure raises $15m

P-Cure CEO: "Completion of the financing round will enable us to make the smart medical solution we have developed accessible to any oncological center that offers radiotherapy.

Boehringer buys #cancer vaccine company AMAL Therapeutics for €325 million http://bit.ly/2JGgrym  #pharma #oncology #biotechpic.twitter.com/2Mf062GmKO

Boehringer buys #cancer vaccine company AMAL Therapeutics for €325 million http://bit.ly/2JGgrym  #pharma #oncology #biotech pic.twitter.com/2Mf062

The declining impact of the US National Institutes of Health on cancer patenting https://go.nature.com/2LjZCN7 pic.twitter.com/ElJnixviYA

The declining impact of the US National Institutes of Health on cancer patenting https://go.nature.com/2LjZCN7  pic.twitter.com/ElJnixviYA

Debate Continues Between Upfront Surgery and Neoadjuvant Chemo in Advanced Ovarian Cancer

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone. https://buff.ly/2lx02DU 

OncLive® Presents State of the Science Summit™ on Multiple Myeloma

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on multiple myeloma on Thursday, July 18, from 5 to 9 p.m. at New York Marriott East Side in New York, New York. The summit will be co-chaired by Ajai Chari, ...

PPD expands patient access to clinical trials via collaboration with cancer center

PPDâs patient enrollment business expands access to cancer patients treated in the community setting as part of a new collaboration with a hospital and outpatient center network.

FDA Approval Sought for Enfortumab Vedotin for Urothelial Cancer

A biologics license application has been submitted to the FDA for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

“End of treatment” bell: reȷoice with those who reȷoice

Having undergone many gruelling months of cancer treatment, I can sympathise with the difficulties that Taylor describes.1 But in my experience—and that of many other patients I encountered (children...

Anti-#Cancer Immune Cells Identified Using Antigen Receptor Barcode Tracker: http://ow.ly/KpqG50v1ULn pic.twitter.com/Ce7wJXbeS8

Anti- #Cancer Immune Cells Identified Using Antigen Receptor Barcode Tracker: http://ow.ly/KpqG50v1ULn  pic.twitter.com/Ce7wJXbeS8

Researchers invent reusable cryoablation device to save women with breast cancer

Women with breast cancer in lower income countries can now be treated using a reusable cryoablation tool, designed by a team of undergraduate researchers. Working out of the The post Researchers invent reusable cryoablation device to save women with breast cancer appeared first on NS Medical Devices.

When hurricanes halt treatment, lung cancer patients die sooner

(Reuters Health) - Lung cancer patients whose radiation treatments are halted by hurricanes or other natural disasters may not live as long as patients who complete treatment without interruptions, a U.S. study suggests.

J&J US Pharma Sales Under Pressure From Pricing And Generics

A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in...  

MSN Labs’ generic Zytiga receives FDA approval

Cancer device created to see if targeted chemotherapy is working

Researchers have created a device that can determine whether targeted chemotherapy drugs are working on individual cancer patients. The portable device, which uses artificial intelligence and biosensors, is up to 95.9% accurate in counting live cancer cells when they pass through electrodes, according to a new study.

Even Before Cancer Is Diagnosed, Some Clones Have Spread

Tumor metastases may not be a late event as the current thinking goes, but may be seeded years before cancer is even diagnosed by clones that were 'born to be bad.' Medscape Medical News

Boehringer looks to oncology vaccines with €325m acquisition

Boehringer takes on AMAL to gain access to its cancer vaccine technology, with a lead candidate due to enter first-in-human studies this month.

Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery

Skyhawk Therapeutics has added Genentech to the growing list of companies it’s working with to find new drugs. The deal with Genentech, a Roche subsidiary, calls for Cambridge, MA-based Skyhawk to use its technology to discover and develop RNA-targeting drugs for cancer and neurological diseases. Under the deal announced Tuesday, Genentech receives an exclusive license […]

Seattle Genetics and Astellas Announce Submission of BLA to FDA for Enfortumab Vedotin for Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the treatment of patients wit...

Top 5 Vendors in the Global Genitourinary Drugs Market 2019-2023 | Technavio

The high prevalence of genitourinary diseases is one of the critical reasons that will drive genitourinary drugs market growth. Bacterial infections or STDs can cause genitourinary disorders. It also includes various carcinomas such as ovarian cancer, cervical cancer, bladder cancer, and prostate cancer. Age-related ailments such as Alzheimer’s and disorders like diabetes, obesity, and multiple...

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer. STING pathway signaling plays an important role in the generation of an immune response directed ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks